EXUDATE INFECTION BIOFILM

Wound healing has always had villains.

Now it has a hero.

AQUACEL® Ag+ Dressings

No dressing does more.†

Available on Drug Tariff from 1st June 2014

ConvaTec

No dressing does more.†

3

Three wound healing villains: exudate, infection and biofilm.

2

Two powerful technologies.

NEW Ag+ Technology

Revolutionary technology **destroys biofilm** and **kills infection-causing bacteria**.*[1-3]

Hydrofiber® Technology

Proven technology that **absorbs and retains excess exudate** to help create an ideal healing environment.*[4-8]

1

One wound healing hero.

AQUACEL® Ag+ Dressings

Currently available in **AQUACEL® Ag+ Extra™** *and* **AQUwACEL® Ag+ Ribbon** *dressings.*

*As demonstrated *in vitro*
†Demonstrated ability to manage excess exudate, infection and biofilm.

Biofilm delays wound healing.

Biofilm is common.

Biofilm is formed when colonies of bacteria secrete a slime layer to protect themselves.[9]

It is involved in approximately 80% of all healthcare infections.[10] The plaque on your teeth, urinary tract infections and eye infections are all linked to biofilm.[11-13]

Even though you can't always see it, **the majority of chronic wounds contain biofilm**[14] – and it's a key cause of delayed wound healing[15] and a precursor to infection.[16]

Biofilm is stubborn.

Biofilm is **difficult to completely remove**[17] – even with debridement – and it **reforms quickly**.[18] Biofilm tolerates:

- Antimicrobials such as PHMB**[19], honey[20], iodine[21,22] and silver[23]
- Antibiotics[24]
- Attempts by the body to clean the wound bed[25] and close the wound[19]



BIOFILM

** polyhexamethylene biguanide

Two powerful technologies working s the key barriers to wound healing.

Ag+ Technology is a unique, silver-containing anti-biofilm formulation that:[26]

- **DISRUPTS** and breaks down biofilm slime to expose bacteria*[1-3]
- **KILLS** a broad spectrum of bacteria, including antibiotic resistant superbugs, with its reservoir of silver*[2,3,27]
- **PREVENTS** biofilm reformation*[2,3]

Proven in the lab

In an *in vitro* biofilm model, **AQUACEL® Ag+ Extra** dressing demonstrated superior ability to **destroy biofilm and prevent reformation.**[28-30]



In this *in vitro* model, mature biofilm was grown on a gauze substrate and confirmed by microscopy. Gauze-biofilm substrates were then transferred to agar plates to create a simulated wound biofilm model; dressings were applied to the biofilm surface, hydrated and covered with an appropriate secondary dressing. Following incubation, the killing effect of the dressing on biofilm-embedded bacteria was assessed at several time points over a maximum of 120 hours. Biofilm reformation was also assessed by inoculating fresh bacteria onto the gauze substrate beneath the dressing, followed by assessment of biofilm presence or absence over a maximum of 96 hours.
*As demonstrated *in vitro*

synergistically to manage

Hydrofiber® Technology helps create an ideal environment for healing – and for Ag+ Technology to work.

- **LOCKS IN** excess exudate, bacteria and biofilm to help minimise cross infection and prevent maceration*[4-7,31,32]
- **MICRO-CONTOURS** to the wound bed, maintaining optimal moisture balance and eliminating dead spaces where bacteria and biofilm can grow*[33-35]
- **RESPONDS** to wound conditions by forming a cohesive gel, while helping to minimise pain associated with dressing changes*[36-38]

Extra absorbency means **longer wear time***[39-41]

Extra strength means **easier removal***[39]



AQUACEL® Ag+ Extra™ dressing

AQUACEL® Ag+ Ribbon dressing

AQUACEL® Ag+ Dressings

*Compared with standard AQUACEL® Ag dressing

AQUACEL® Ag+ Dressings – the family

Proven in scientifically controlled wounds

In an adapted *in vivo* biofilm model[19], **Ag+ Technology** in combination with **Hydrofiber® Technology** demonstrated:*

- A significantly greater reduction of **biofilm** vs. a PHMB gauze.[41]

95%

greater reduction by day 6 ($p<0.05$)



- A significantly greater rate of **epithelialisation** and **granulation** vs. a PHMB gauze.[41]

48%

more granulation tissue by day 6 ($p<0.05$)



24%

more epithelial tissue by day 6 ($p<0.05$)



*AQUACEL® Ag+ dressing was used in this study

ily of wound healing heroes.

Demonstrated wound healing in the clinic[42]

In a prospective, multi-Centre, non-comparative study on 42 chronic venous leg ulcer patients with at-risk or infected wounds^ where biofilm is highly likely, **Ag+ Technology** in combination with **Hydrofiber® Technology** demonstrated:*

54%
reduction in ulcer area for **all** wounds

70%
reduction in ulcer area for **infected** wounds




Day 1


Day 28


Day 49 - healed


Day 1


Day 22


Day 56 - healed

^10 infected (exhibiting all 5 signs of clinical infection) and 32 at-risk wounds (exhibiting at least 3 of the 5 classical clinical signs of infection)
*AQUACEL® Ag+ dressing was used in this study

AQUACEL® Ag+ Dressings *No dressing does more†.*

Add **AQUACEL® Ag+ Dressings** to your protocol of care for chronic and acute wounds that are **infected** or **at risk of infection**.

Perfect partners: AQUACEL® Ag+ Dressings and AQUACEL® Foam

Dressing Size	Dressings per box	Product Code	NHS Code	PIP Code
AQUACEL® Ag+ Extra™				
5 cm x 5 cm	10	413566	ELY514	386-2703
10 cm x 10 cm	10	413567	ELY515	386-2695
15 cm x 15 cm	5	413568	ELY516	386-2711
20 cm x 30 cm	5	413569	ELY517	386-2679
4 cm x 10 cm	10	413581	ELY520	386-0350
4 cm x 20 cm	10	413598	ELY521	386-0368
4 cm x 30 cm	10	413599	ELY522	386-2687
AQUACEL® Ag+ *Ribbon Dressing*				
2 cm x 45 cm	5	413571	ELY519	386-2737
1 cm x 45 cm	5	413570	ELY518	386-2729

Dressing Size	Dressings per box	Product Code	NHS Code	PIP Code
AQUACEL® Foam *Adhesive*				
8 cm x 8 cm	10	420804	ELY428	378-1820
10 cm x 10 cm	10	420680	ELY417	370-2784
12.5 cm x 12.5 cm	10	420619	ELY418	370-2792
17.5 cm x 17.5 cm	10	420621	ELY419	370-2800
21 cm x 21 cm	5	420623	ELY420	370-2818
25 cm x 30 cm	5	420624	ELY421	370-7361
19.8 cm x 14 cm Heel	5	420625	ELY422	370-7486
20 cm x 16.9 cm Sacral	5	420626	ELY423	370-6041
AQUACEL® Foam *Non-Adhesive*				
5 cm x 5 cm	10	420631	ELY412	369-9311
10 cm x 10 cm	10	420633	ELY413	369-9329
15 cm x 15 cm	5	420635	ELY414	370-2750
20 cm x 20 cm	5	420636	ELY416	370-2776
15 cm x 20 cm	5	420637	ELY415	370-2768

1. Physical Disruption of Biofilm by AQUACEL® Ag+ Wound Dressing. Scientific Background Report. WHRI3850 MA232, 2013, Data on file, ConvaTec Inc. **2.** Antimicrobial activity and prevention of biofilm reformation by AQUACEL™ Ag+ EXTRA dressing. Scientific Background Report. WHRI3857 MA236, 2013, Data on file, ConvaTec Inc. **3.** Antimicrobial activity against CA-MRSA and prevention of biofilm reformation by AQUACEL™ Ag+ EXTRA dressing. Scientific Background Report. WHRI3875 MA239, 2013, Data on file, ConvaTec Inc. **4.** Newman GR, Walker M, Hobot JA, Bowler PG, 2006. Visualisation of bacterial sequestration and bacterial activity within hydrating Hydrober™ wound dressings. *Biomaterials*; 27: 1129-1139. **5.** Walker M, Hobot JA, Newman GR, Bowler PG, 2003. Scanning electron microscopic examination of bacterial immobilization in a carboxymethyl cellulose (AQUACEL™) and alginate dressing. *Biomaterials*; 24: 883-890. **6.** Bowler PG, Jones SA, Davies BJ, Coyle E, 1999. Infection control properties of some wound dressings. *J. Wound Care*; 8: 499-502. **7.** Walker M, Bowler PG, Cochrane CA, 2007. *In vitro* studies to show sequestration of matrix metalloproteinases by silver-containing wound care products. *Ostomy/Wound Management*. 2007; 53: 18-25. **8.** Assessment of the *in vitro* Physical Properties of AQUACEL EXTRA, AQUACEL Ag EXTRA and AQUACEL Ag+ EXTRA dressings. Scientific background report. WHRIA3817 TA297, 2013, Data on file, ConvaTec Inc. **9.** Bjarnsholt T, 2013. The role of bacterial biofilms in chronic infections. *APMIS*. 121. 1-51. **10.** Research on microbial biofilms. National Institute of Dental and Craniofacial Research. http://grants.nih.gov/grants/guide/pa-files/PA-03-047.html; Sept. 9, 1997. **11.** Marsh PD, Bradshaw DJ, 1995. Dental plaque as a biofilm. *J. Industr. Microbial*; 15: 169-175. **12.** Trautner BW, Darouiche RO, 2004. Role of biofilm in catheter-associated urinary tract infection. *Am J Infect Control*; 32: 177-183. **13.** Elder MJ, Stapleton F, Evans E, Dart JK, 1995. Biofilm-related Infections in Ophthalmology. *Eye (Lond.)* 9: 102-109. **14.** James GA, Swogger E, Wolcott R, Pulcini EL, Secor P, Sestrich J, et al, 2008. Biofilms in Chronic Wounds. *Wound Rep Regen*; 16: 37-44. **15.** Metcalf D, Bowler P, 2013. Biofilm delays wound healing: A review of the evidence. *Burns & Trauma*. 1: 5-12. **16.** Percival SL, Bowler PG, 2004. Biofilms and their potential role in wound healing. *WOUNDS*, 16: 234-240. **17.** Wolcott RD, Rumbaugh KP, James G, Schultz G, Phillips P, Yang O, et al, 2010. Biofilm maturity studies indicate sharp debridement opens a time-dependent therapeutic window. *J Wound Care*; 19: 320-328. **18.** Wolcott RD, Kennedy JP, Dowd SE, 2009. Regular debridement is the main tool for maintaining a healthy wound bed in most chronic. *J Wound Care*; 18: 54-56. **19.** Gurjala AN, Geringer MR, Seth AK, Hong SJ, Smeltzer MS, Galiano RA, et al, 2011. Development of a novel, highly quantitative *in vivo* model for the study of biofilm-impaired cutaneous wound healing. *Wound Rep Reg*. 19: 400-410. **20.** Brackman G, De Meyer L, Nelis HJ, Coenye T, 2013. Biofilm inhibitory and eradicating activity of wound care products against Staphylococcus aureus and Staphylococcus epidermidis biofilms in an *in vitro* chronic wound model. *J Appl Miocrobial*; 114: 1833-42. **21.** Darouiche RO, Mansouri MD, Gawande PV, Madhyastha S. Antimicrobial and antibiofilm efficacy of triclosan and DispersinB combination. *J Antimicrob Chemother*. 2009 Jul;64(1):88-93. **22.** Thorn RM, Greenman J. A novel *in vitro* flat-bed perfusion biofilm model for determining the potential antimicrobial efficacy of topical wound treatments. *J Appl Microbiol*. 2009 Dec 1;107(6):2070-9. **23.** Bjarnsholt B, Kirketerp-Moller K, Kristiansen S, Phipps R, Nielsen AK, Jensen Po, et al, 2007. Silver against *Pseudomonas aeruginosa* biofilms. *APMIS* 115: 921-8. **24.** Stewart PS, Costerton JW, 2001. Antibiotic resistance of bacteria in biofilms. *Lancet*; 358: 135-138. **25.** Thurlow LR, Hanke ML, Fritz T, Angie A, Aldrich A, Williams SH, Engebretsen IL, et al, 2011. *Staphylococcus aureus* biofilms prevent macrophage phago-cytosis and attenuate inflammation *in vivo*. *J Immunol*; 186: 6585-96. **26.** Composition comprising antimicrobial metal ions and a quaternary cationic surfactant. Scientific Background Report. WO 2012136968 A1, 2012, Data on file, ConvaTec Inc. **27.** Bowler PG, Welsby S, Towers V, Booth V, Hogarth A, Rowlands V, Joseph A, et al, 2012. Multidrug-resistant organisms, wounds and topical antimicrobial protection. *Int Wound J*. 9: 387-396. **28.** Antimicrobial activity against CA-MRSA and prevention of biofilm reformation by AQUACEL™ Ag+ EXTRA Dressing and Acticoat 7 Dressing. Scientific Background Report. WHRI3876 MA240, 2013, Data on file, ConvaTec Inc. **29.** Antimicrobial Activity and Prevention of Biofilm Reformation by AQUACEL® Ag+ EXTRA Dressing and Acticoat 7 Dressing. WHRI3858 MA237, 2013, Data on file, ConvaTec Inc. **30.** Antimicrobial Activity and Prevention of Biofilm Reformation by AQUACEL® Ag EXTRA Dressing and Silvercel® Non Adherent Dressing. WHRI3877 MA241, 2013, Data on file, ConvaTec Inc. **31.** Walker M and Parsons D, 2010. Hydrofiber Technology: its role in exudate management. *Wounds UK*; 6: 31-38. **32.** Parsons D, Bowler PG, Myles V, Jones SA, 2005. Silver antimicrobial dressings in wound management: A comparison of antibacterial, physical and chemical characteristics. *WOUNDS*; 17: 222-232. **33.** Jones SA, Bowler PG, Walker M, 2005. Antimicrobial activity of silver-containing dressings is influenced by dressing conformability with a wound surface. *WOUNDS*; 17: 263-270. **34.** Bowler P, Jones S, Towers V, Booth R, Parsons D, Walker M, 2010. Dressing conformability and silver-containing wound dressings. *Wounds UK*; 6: 14-20. **35.** Walker M, Jones S, Parsons D, Booth R, Cochrane C, Bowler P, 2011. Evaluation of low-adherent antimicrobial dressings. *Wounds UK*; 7: 32-45. **36.** Barnea Y, Armir A, Leshem D, Zaretski A, Weiss J, Shafir R, et al, 2004. Clinical comparative study of Aquacel and paraffin gauze dressing for split-skin donor site treatment. *Ann Plast Surg*; 53: 132-136. **37.** Kogan L, Moldavsky M, Szvalb S, Govrin-Yehudain J, 2004. Comparative study of Aquacel and Silverol treatment in burns. *Ann Burns Fire Disasters*; 17: 201-207. **38.** Brunner U, Eberlein T, 2000. Experiences with hydrofibres in the moist treatment of chronic wounds, in particular of diabetic foot. *VASA*; 29: 253-257. **39.** Assessment of the *in vitro* physical properties of AQUACEL Ag, AQUACEL Ag EXTRA and AQUACEL Ag+ Dressings, Scientific Background Report. WHRI3817 TA297, 2013, Data on file, ConvaTec Inc. **40.** Harding K, Ivans N, Cains J, An opened randomized comparative study to evaluate the clinical and economic performance of two absorbent dressings in venus leg ulcers. Poster presented at EWMA; May 15-17 2013; Copenhagen, Denmark. **41.** Parsons D, Mustoe T, Seth A. A new anti-biofilm Hydrofiber™ dressing: an *in vivo* investigation. Poster presented at Wounds UK; Nov 11-13 2013; Harrogate, UK. **42.** Harding K, Ivans N, Cains J, Peters K, Parsons D. A new anti-biofilm dressing – a clinical study. Poster presented at EWMA; May 15-17 2013; Copenhagen, Denmark.

To learn more about AQUACEL® Ag+ dressings or to arrange a visit from your ConvaTec representative, please call **0800 289 738 (UK)** or **1800 946 938 (ROI)**
www.convatec.co.uk

AQUACEL® Ag+ Dressings

†Demonstrated ability to manage excess exudate, infection and biofilm.

ConvaTec